Journals / Glokom Katarakt / 2020 / Cilt: 15 - Sayı: 4

Preoperative Intracameral and Intravitreal Afl ibercept Injection, Pars Plana Vitrectomy and Ahmed Glaucoma Valve Implantation in Refractory Neovascular Glaucoma

Pages
236–239
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Also, in these patients, glaucoma drainage implants have an important role in the control of intraocular pressure and glaucoma management.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background: Medical and surgical management of one-eyed patient with neovascular glaucoma secondary to proliferative diabetic retinopathy, chronic myeloid leukemia and chronic renal failure.
📊
Key Findings & Data:Case report: A 68-year-old male patient with type 2 diabetes mellitus, chronic myeloid leukemia and chronic renal failure presented with sudden loss of vision in the right eye.
💡
Conclusion & Impact:Also, in these patients, glaucoma drainage implants have an important role in the control of intraocular pressure and glaucoma management.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Background: Medical and surgical management of one-eyed patient with neovascular glaucoma secondary to proliferative diabetic retinopathy, chronic myeloid leukemia and chronic renal failure. Case report: A 68-year-old male patient with type 2 diabetes mellitus, chronic myeloid leukemia and chronic renal failure presented with sudden loss of vision in the right eye. In the left eye, there was visual acuity at the level of light perception and glaucomatous optic atrophy. In the right eye, the best-corrected visual acuity was 0.1 and anterior segment examination revealed rubeosis iridis and diffuse peripheral anterior synechia. In fundus examination, there were fi ndings of diabetic retinopathy with cup: disc ratio of 4:10, peripapillary splinter hemorrhage and intraocular pressure of 40 mmHg. Despite initiation the maximal medical anti-glaucomatous treatment, it was failed to reduce IOP. Optical medium did not allow panretinal laser photocoagulation. Anterior chamber (half dose) and intravitreal (full dose) anti-VEGF (afl ibercept) injections were performed. Following regression of rubeosis iridis, pars plana vitrectomy and panretinal endolaser photocoagulation were performed in combination with cataract surgery. Ahmed valve tube implantation was performed because the postoperative intraocular pressure was 28 mmHg. Intraocular pressure decreased to 10 mmHg. Here, we highlighted the points to be considered in the management of a one-eyed neovascular glaucoma case. Conclusion: Intracameral and intravitreal anti-VEGF (afl ibercept) injection, panretinal laser photocoagulation, pars plana vitrectomy are effective and reliable treatments for regression of rubeosis iridis in patients with neovascular glaucoma. Also, in these patients, glaucoma drainage implants have an important role in the control of intraocular pressure and glaucoma management.

🔖

Cite This Article

YILMAZ, A. C., CAKIR, B. A., KOYLU, M. T., KUCUKEVCILIOGLU, M. (2020). Preoperative Intracameral and Intravitreal Afl ibercept Injection, Pars Plana Vitrectomy and Ahmed Glaucoma Valve Implantation in Refractory Neovascular Glaucoma. Glokom Katarakt, Cilt: 15 - Sayı: 4, 236–239. https://ajindex.com/articles/158081

References (15)

  1. Shazly TA, Latina MA. Neovascular glaucoma: etiology, diagnosis and prognosis. Semin Ophthalmol 2009;24:113-21
  2. Noma H, Mimura T, Yasuda K, et al. Vascular endothelial growth factor and its soluble receptors-1 and -2 in iris neovascularization and neovascular glaucoma. Ophthalmologica 2014;232:102-9
  3. Wolf A, von Jagow B, Ulbig M, et al. Intracameral injection of bevacizumab fort he treatment of neovascular glaucoma. Ophthalmologica. 2011;226:51-56
  4. Ohr M, Kaiser PK. Intravitreal afl ibercept injection for neovascular (wet) age-related macular degeneration. Expert Opin Pharmacother 2012; 13:585-91
  5. Papadopoulos N, Martin J, Ruan Q et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012;15:171-85
  6. SooHoo JR, Seibold LK, Pantcheva MB, et al. Afl ibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol. 2015 Dec;43:803-7
  7. Mermoud A, Salmon JF, Alexander P, et al. Molteno tube implantation for neovascular glaucoma. Long term results and factors infuencing the outcome. Ophthalmology. 1993;100:897-902
  8. Wand M, Dueker DK, Aiello LM, Grant WM. Effects of panretinal photocoagulation on rubeosis iridis, angle neovascularization, and neovascular glaucoma. Am J Ophthalmol 1978; 86:332-9
  9. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007; 27: 816-24
  10. Tripathi RC, Li J, Tripathi BJ, Chalam KV, et al. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105: 232-7
  11. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective, observational case series. Arch Ophthalmol. 2011;129:145-50
  12. Duch S, Buchacra O, Milla E, et al. Intracameral bevacizumab (Avastin) for neovascular glaucoma: a pilot study in 6 patients. J Glaucoma. 2009;18:140-3
  13. Rasier R, Artunay Ö, Yüzbaşıoğlu E, et al. Neovasküler glokomlu olguda eş zamanlı intravitreal ve intrakameral bevacizumab uygulaması. Glo-Kat 2008;3:135-38
  14. Ha JY, Lee TH, Sung MS, et al. Effi cacy and safety of intracameral bevacizumab for treatment of neovascular glaucoma. Korean J Ophthalmol. 2017;31:538-47
  15. Ma KT, Yang JY, Kim NR, et al. Surgical results of Ahmed valve implantation with intraoperative bevacizumab inj